Literature DB >> 8388204

Antimicrobial effects of a new carboxyquinolone drug, Q-35, on five serogroups of Leptospira interrogans.

I Takashima1, M Ngoma, N Hashimoto.   

Abstract

New carboxyquinolone drugs, including the recently developed Q-35, were evaluated for their in vitro potency against five serogroups of Leptospira interrogans. Q-35, ofloxacin, ciprofloxacin, and tosufloxacin showed MICs (0.05 to 0.20 microgram/ml) comparable to those of tetracycline. However, MBCs of these drugs varied between 10- and 100-fold above the MIC for most strains tested. Q-35 was shown to be active against L. interrogans in vitro as judged by the MICs obtained.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8388204      PMCID： PMC187807          DOI： 10.1128/AAC.37.4.901

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Leptospirosis. A comparison of symptomatic and penicillin therapy.

Authors:  R S KOCEN
Journal:  Br Med J       Date:  1962-04-28

2.  Hemolysis of sheep erythrocytes sensitized with leptospiral extracts.

Authors:  C D COX
Journal:  Proc Soc Exp Biol Med       Date:  1955-12

3.  Penicillin in leptospirosis.

Authors:  L Clein
Journal:  Br Med J       Date:  1973-08-11

4.  Leptospirosis.

Authors:  L H Turner
Journal:  Br Med J       Date:  1969-01-25

5.  In vitro susceptibilities of five Leptospira strains to 16 antimicrobial agents.

Authors:  S Oie; K Hironaga; A Koshiro; H Konishi; Z Yoshii
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

6.  Penicillins, cephalosporins, and tetracyclines in treatment of hamsters with fatal leptospirosis.

Authors:  A D Alexander; P L Rule
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

7.  In vitro antibacterial activity of Q-35, a new fluoroquinolone.

Authors:  T Ito; M Otsuki; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

8.  Efficacy of ciprofloxacin against Leptospira interrogans serogroup icterohaemorrhagiae.

Authors:  I Shalit; A Barnea; A Shahar
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191
  8 in total
  7 in total

Review 1.  Leptospirosis.

Authors:  P N Levett
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

2.  In vitro susceptibilities of seven Leptospira species to traditional and newer antibiotics.

Authors:  Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

3.  Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.

Authors:  Matthew E Griffith; James E Moon; Erica N Johnson; Kyra P Clark; Joshua S Hawley; Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

4.  Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.

Authors:  Roseanne A Ressner; Matthew E Griffith; Miriam L Beckius; Guillermo Pimentel; R Scott Miller; Katrin Mende; Susan L Fraser; Renee L Galloway; Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

5.  Determination of susceptibilities of 26 Leptospira sp. serovars to 24 antimicrobial agents by a broth microdilution technique.

Authors:  Clinton K Murray; Duane R Hospenthal
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  Broth microdilution susceptibility testing for Leptospira spp.

Authors:  Clinton K Murray; Duane R Hospenthal
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  In vitro susceptibilities of Leptospira spp. and Borrelia burgdorferi isolates to amoxicillin, tilmicosin, and enrofloxacin.

Authors:  Doo Kim; Dorsey Kordick; Thomas Divers; Yung Fu Chang
Journal:  J Vet Sci       Date:  2006-12       Impact factor: 1.672
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.